Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial

Area of Science:

• Clinical Medicine
• Pharmacotherapy
• Smoking Cessation

Background:

• Adaptive pharmacotherapy, tailoring medication based on patient response, is underutilized in smoking cessation.
• Previous research indicated efficacy for adaptive nicotine patch treatment, but adaptive varenicline and real-world clinical application require further study.

Purpose of the Study:

• To compare the efficacy of adaptive pharmacotherapy versus standard pharmacotherapy for smoking cessation in a clinical practice setting.
• To determine if adaptive treatment yields higher smoking abstinence rates.

Main Methods:

• A double-blinded, placebo-controlled randomized clinical trial was conducted.
• Participants chose between varenicline or nicotine patches and were randomized to adaptive or standard treatment arms.
• Adaptive treatment involved adjusting medication (adding bupropion if needed) based on early response, while standard treatment followed a fixed regimen.

Main Results:

• Adaptive pharmacotherapy resulted in significantly higher biochemically verified 30-day continuous smoking abstinence at 12 weeks (24% vs. 9%, OR 3.38, P=.004).
• This effect was particularly pronounced in the varenicline subgroup (28% vs. 8%, OR 4.54).
• Sleep problems were more frequent in the adaptive varenicline group.

Conclusions:

• Adaptive pharmacotherapy demonstrated efficacy for smoking cessation in a clinical practice setting.
• This personalized approach represents a more effective strategy for aiding patients in quitting smoking.
• Further research may explore optimizing adaptive strategies and managing side effects like sleep disturbances.